150 related articles for article (PubMed ID: 7510237)
1. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.
Junnikkala S; Hakulinen J; Meri S
Eur J Immunol; 1994 Mar; 24(3):611-5. PubMed ID: 7510237
[TBL] [Abstract][Full Text] [Related]
2. Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement.
Jokiranta TS; Meri S
J Immunol; 1993 Aug; 151(4):2124-31. PubMed ID: 7688394
[TBL] [Abstract][Full Text] [Related]
3. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
Hakulinen J; Meri S
Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement.
Coral S; Fonsatti E; Sigalotti L; De Nardo C; Visintin A; Nardi G; Colizzi F; Colombo MP; Romano G; Altomonte M; Maio M
J Cell Physiol; 2000 Dec; 185(3):317-23. PubMed ID: 11056001
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
Brasoveanu LI; Fonsatti E; Visintin A; Pavlovic M; Cattarossi I; Colizzi F; Gasparollo A; Coral S; Horejsi V; Altomonte M; Maio M
J Clin Invest; 1997 Sep; 100(5):1248-55. PubMed ID: 9276743
[TBL] [Abstract][Full Text] [Related]
7. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction.
Väkevä A; Laurila P; Meri S
Lab Invest; 1992 Nov; 67(5):608-16. PubMed ID: 1279272
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
[TBL] [Abstract][Full Text] [Related]
9. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
[TBL] [Abstract][Full Text] [Related]
10. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of CD59 on colonic adenocarcinoma cells.
Bjørge L; Vedeler CA; Ulvestad E; Matre R
Eur J Immunol; 1994 Jul; 24(7):1597-603. PubMed ID: 7517877
[TBL] [Abstract][Full Text] [Related]
12. CD59 efficiently protects human NT2-N neurons against complement-mediated damage.
Pedersen ED; Aass HC; Rootwelt T; Fung M; Lambris JD; Mollnes TE
Scand J Immunol; 2007; 66(2-3):345-51. PubMed ID: 17635812
[TBL] [Abstract][Full Text] [Related]
13. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
14. Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59.
Kennedy SP; Rollins SA; Burton WV; Sims PJ; Bothwell AL; Squinto SP; Zavoico GB
Transplantation; 1994 May; 57(10):1494-501. PubMed ID: 7515200
[TBL] [Abstract][Full Text] [Related]
15. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
Capey S; van den Berg CW
Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
[TBL] [Abstract][Full Text] [Related]
16. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
19. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.
Brasoveanu LI; Altomonte M; Gloghini A; Fonsatti E; Coral S; Gasparollo A; Montagner R; Cattarossi I; Simonelli C; Cattelan A
Int J Cancer; 1995 May; 61(4):548-56. PubMed ID: 7538980
[TBL] [Abstract][Full Text] [Related]
20. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]